Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.
Andrea Sabens net worth and biography

Andrea Sabens Biography and Net Worth

CAO of Lantheus
Ms. Andrea Sabens is a Chief Accounting Officer at Lantheus Holdings, Inc. She received her undergraduate degree from the University of New Hampshire, a graduate degree from Southern New Hampshire University and an MBA from Southern New Hampshire University.

What is Andrea Sabens' net worth?

The estimated net worth of Andrea Sabens is at least $3.42 million as of January 17th, 2023. Ms. Sabens owns 60,846 shares of Lantheus stock worth more than $3,419,545 as of January 29th. This net worth evaluation does not reflect any other investments that Ms. Sabens may own. Learn More about Andrea Sabens' net worth.

How old is Andrea Sabens?

Ms. Sabens is currently 44 years old. There are 6 older executives and no younger executives at Lantheus. The oldest executive at Lantheus is Ms. Mary Anne Heino, CEO, Pres & Director, who is 63 years old. Learn More on Andrea Sabens' age.

How do I contact Andrea Sabens?

The corporate mailing address for Ms. Sabens and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected] Learn More on Andrea Sabens' contact information.

Has Andrea Sabens been buying or selling shares of Lantheus?

During the last ninety days, Andrea Sabens has sold $20,446.42 in Lantheus stock. Most recently, Andrea Sabens sold 386 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $52.97, for a transaction totalling $20,446.42. Following the completion of the sale, the chief accounting officer now directly owns 60,846 shares of the company's stock, valued at $3,223,012.62. Learn More on Andrea Sabens' trading history.

Who are Lantheus' active insiders?

Lantheus' insider roster includes Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.

Are insiders buying or selling shares of Lantheus?

During the last year, insiders at the medical equipment provider sold shares 31 times. They sold a total of 214,604 shares worth more than $13,073,245.77. The most recent insider tranaction occured on January, 17th when CAO Andrea Sabens sold 386 shares worth more than $20,446.42. Insiders at Lantheus own 1.6% of the company. Learn More about insider trades at Lantheus.

Information on this page was last updated on 1/17/2023.

Andrea Sabens Insider Trading History at Lantheus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2023Sell386$52.97$20,446.4260,846View SEC Filing Icon  
12/15/2022Sell386$53.75$20,747.5061,232View SEC Filing Icon  
10/17/2022Sell386$70.50$27,213.0062,004View SEC Filing Icon  
9/15/2022Sell386$85.83$33,130.3862,390View SEC Filing Icon  
8/15/2022Sell386$82.82$31,968.5262,776View SEC Filing Icon  
7/18/2022Sell1,093$71.47$78,116.7163,162View SEC Filing Icon  
7/15/2022Sell386$69.12$26,680.3264,255View SEC Filing Icon  
6/15/2022Sell386$62.87$24,267.8264,441View SEC Filing Icon  
3/1/2022Sell2,409$48.04$115,728.36View SEC Filing Icon  
1/18/2022Sell1,242$26.93$33,447.06View SEC Filing Icon  
12/15/2021Sell1,242$26.72$33,186.24View SEC Filing Icon  
11/15/2021Sell1,242$30.47$37,843.74View SEC Filing Icon  
10/15/2021Sell1,242$23.71$29,447.82View SEC Filing Icon  
8/16/2021Sell1,242$25.46$31,621.3267,312View SEC Filing Icon  
See Full Table

Andrea Sabens Buying and Selling Activity at Lantheus

This chart shows Andrea Sabens's buying and selling at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lantheus Company Overview

Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More

Today's Range

Now: $56.20
Low: $55.05
High: $56.72

50 Day Range

MA: $53.91
Low: $47.76
High: $62.08

2 Week Range

Now: $56.20
Low: $23.51
High: $87.47


596,503 shs

Average Volume

844,254 shs

Market Capitalization

$3.87 billion

P/E Ratio


Dividend Yield



The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.